Issue Highlights
- Low-Risk Lyo at Ben Venue Labs
- IBM on the Need to Partner
- Baxter Admits Distributing Contaminated Flu Product

Low-Risk Lyophilization
In the CMO world, few know lyo like Ben Venue. Here, BVL experts Brian Bucur and Tim Smith share best practices from their decades with the company.

Reconstituting at the Point of Use
Hyaluron Contract Manufacturing is working on new approaches that allow the user to reconstitute lyophilized drugs within the syringe at the point of use, eliminating dosing variability and overfill waste. CEO Shawn Kinney talks about his company and its new approach to filling, and reconstituting, lyophilized drugs.

Imperfect Harmony: Life Sciences Companies Must Partner
to Thrive
A just-released IBM study suggests that if life sciences companies do not collaborate, they risk delays in production. The survey, "An Imperfect Harmony: Alliances within the Life Sciences Industry," says that while the number of partnerships between larger and smaller life-sciences companies has increased over the past decade, the companies' abilities to effectively work together and produce new medicines has not been achieved.

Featured Webcast  

Redefining Pharmaceutical Process Validation
When: March 26, 2009
FDA's new guidance spells out clearly a new philosophy toward process validation that is rooted in process understanding, and allows more flexibility. In this program, experts discuss the opportunities presented by the guidance, how they differ from traditional approaches and what it all means for technology investment, plant debottlenecking, improving existing operations and validating and commissioning new plants.